Početna stranicaREPCF • OTCMKTS
add
RepliCel Life Sciences Inc
Preth. zaklj. cijena
0,010 $
Tržišna kapitalizacija
551,83 tis. CAD
Prosječna količina
2,98 tis.
P/E omjer
-
Prinos dividende
-
Glavno tržište vrijednosnica
CVE
Vijesti s tržišta
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
(CAD) | ruj 2024.info | Godišnja promjena |
---|---|---|
Prihod | 88,43 tis. | 0,00 % |
Operativni troškovi | 168,09 tis. | −59,39 % |
Neto dohodak | −216,22 tis. | 73,59 % |
Neto profitabilnost | −244,50 | 73,59 % |
Zarada po dionici | — | — |
EBITDA | −79,52 tis. | 75,57 % |
Efektivna porezna stopa | — | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
(CAD) | ruj 2024.info | Godišnja promjena |
---|---|---|
Gotovinska i kratkoročna ulaganja | 10,46 tis. | −67,78 % |
Ukupna imovina | 150,97 tis. | −54,45 % |
Ukupne obveze | 5,34 mil. | −23,30 % |
Ukupni kapital | −5,19 mil. | — |
Dionice u optjecaju | 65,00 mil. | — |
Cijena prema knjigovodstvenoj vrijednosti | −0,12 | — |
Povrat imovine | −123,05 % | — |
Povrat kapitala | 5,23 % | — |
Tok novca
Neto promjena novca
(CAD) | ruj 2024.info | Godišnja promjena |
---|---|---|
Neto dohodak | −216,22 tis. | 73,59 % |
Gotovina od poslovanja | −53,11 tis. | 73,48 % |
Gotovina iz ulaganja | 0,00 | — |
Gotovina iz financiranja | 44,63 tis. | 4.463.500,00 % |
Neto promjena novca | −8,48 tis. | 95,77 % |
Slobodan tok novca | −86,26 tis. | 63,60 % |
Više
RepliCel Life Sciences is a Canadian regenerative medicine company based in Vancouver, British Columbia. The company focuses on development of cell therapies using a patient's own cells. The company has treatment development activities targeting chronic tendon injuries which have failed to heal properly, and hair restoration. The company's expertise lies in isolation and exploitation of different cell populations found in the human hair follicle.
The company's business model is focused on establishing proof-of-concept for treatments leading to acquisition by a larger company. An alternative business model has been reported which does not involve acquisition but rather partnership where technologies and methods are licensed to a partner which will commercialize them. Wikipedia
Osnovano
1967
Web-lokacija
Zaposlenici
1